KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Acquisitions & Divestments: 2009-2024

Historic Change in Acquisitions & Divestments for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $340.4 million.

  • Nektar Therapeutics' Change in Acquisitions & Divestments fell 15.90% to $54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.8 million, marking a year-over-year decrease of 40.29%. This contributed to the annual value of $340.4 million for FY2024, which is 47.71% down from last year.
  • As of FY2024, Nektar Therapeutics' Change in Acquisitions & Divestments stood at $340.4 million, which was down 47.71% from $650.9 million recorded in FY2023.
  • Nektar Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $1.4 billion during FY2020, with a 5-year trough of $340.4 million in FY2024.
  • For the 3-year period, Nektar Therapeutics' Change in Acquisitions & Divestments averaged around $605.8 million, with its median value being $650.9 million (2023).
  • Data for Nektar Therapeutics' Change in Acquisitions & Divestments shows a maximum YoY tumbled of 47.71% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Change in Acquisitions & Divestments stood at $1.4 billion in 2020, then fell by 19.48% to $1.2 billion in 2021, then declined by 29.20% to $826.2 million in 2022, then declined by 21.22% to $650.9 million in 2023, then slumped by 47.71% to $340.4 million in 2024.